Literature DB >> 7528729

Cytokines and progenitor cells of granulocytopoiesis in peripheral blood of patients with bacterial infections.

C Selig1, W Nothdurft.   

Abstract

To investigate the physiological role of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in the adaptation mechanisms of myelopoiesis to enhanced demand, we studied both cytokines and their myeloid target cells in hematologically healthy patients suffering from acute bacterial infections. Endogenous serum levels of G-CSF and GM-CSF, granulocyte-macrophage colony-forming cell (GM-CFC) concentrations, and differential counts were determined for the peripheral blood of 57 patients with clinically apparent bacterial infections (26 males and 31 females aged 16 to 89 years) and 18 healthy controls (8 males and 10 females aged 23 to 84 years). Patients were selected for acute-phase protein and at least two additional clinical signs reflecting a bacterial infection. Patients showed significantly higher numbers of myeloid progenitor cells than controls (median, 68 versus 26 GM-CFC/ml; P < or = 0.01). G-CSF but not GM-CSF levels were found to be elevated (> or = 50 to 863 pg/ml). In the acute stage of infection, progenitor and cytokine levels were not influenced by gender, differences in therapy, or localization of the infection. Progenitor and G-CSF levels were not associated with absolute neutrophil counts or C-reactive protein. However, a negative correlation between number of GM-CFC per milliliter and age (R = -0.47; P < or = 0.001) and an inverse relationship between the incidence of high GM-CFC concentrations and elevated G-CSF levels (phi = -0.34; P < or = 0.01) were found. Combining both parameters into a cytokine-progenitor pattern, we observed a highly significant age-dependent response of myelopoiesis to inflammation (P < or = 0.001). Younger patients had high progenitor counts (> 75 GM-CFC/ml) associated with G-CSF levels below 50 pg/ml, whereas for the older patients, the reverse pattern was predominant. The results indicate that the age-dependent myelopoietic response to acute bacterial infections is characterized by an inverse relationship between progenitor cells and G-CSF. The observed cytokine-progenitor patterns could have implications for therapy with G-CSF and the prognosis of infectious diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7528729      PMCID: PMC172964          DOI: 10.1128/iai.63.1.104-109.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

Review 1.  Hematopoietic growth factors in bone marrow transplantation.

Authors:  R Mertelsmann; F Herrmann; T Hecht; G Schulz
Journal:  Bone Marrow Transplant       Date:  1990-08       Impact factor: 5.483

2.  Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group.

Authors:  T Calandra; J D Baumgartner; G E Grau; M M Wu; P H Lambert; J Schellekens; J Verhoef; M P Glauser
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

3.  Proliferation and maturation of human bone marrow cells in infectious diseases.

Authors:  P Dörmer; L Hültner; H G Mergenthaler
Journal:  Pathol Res Pract       Date:  1990-02       Impact factor: 3.250

Review 4.  Myeloid haemopoietic growth factors.

Authors:  A D Whetton; T M Dexter
Journal:  Biochim Biophys Acta       Date:  1989-12-17

5.  A new bioassay for human granulocyte colony-stimulating factor (hG-CSF) using murine myeloblastic NFS-60 cells as targets and estimation of its levels in sera from normal healthy persons and patients with infectious and hematological disorders.

Authors:  N Shirafuji; S Asano; S Matsuda; K Watari; F Takaku; S Nagata
Journal:  Exp Hematol       Date:  1989-02       Impact factor: 3.084

6.  Therapeutic use of recombinant human G-CSF (rhG-CSF) in a canine model of sublethal and lethal whole-body irradiation.

Authors:  T J MacVittie; R L Monroy; M L Patchen; L M Souza
Journal:  Int J Radiat Biol       Date:  1990-04       Impact factor: 2.694

7.  Treatment of cancer patients with endotoxin induces release of endogenous cytokines.

Authors:  A Mackensen; C Galanos; R Engelhardt
Journal:  Pathobiology       Date:  1991       Impact factor: 4.342

8.  Response of serum interleukin-6 in patients undergoing elective surgery of varying severity.

Authors:  A M Cruickshank; W D Fraser; H J Burns; J Van Damme; A Shenkin
Journal:  Clin Sci (Lond)       Date:  1990-08       Impact factor: 6.124

9.  Levels of serum granulocyte colony-stimulating factor in patients with infections.

Authors:  M Kawakami; H Tsutsumi; T Kumakawa; H Abe; M Hirai; S Kurosawa; M Mori; M Fukushima
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

10.  [Mechanism of stimulation of spleen mononuclear cells by gram-positive bacterial peptidoglycan].

Authors:  M Sashida
Journal:  Nichidai Koko Kagaku       Date:  1989-09
View more
  13 in total

1.  Expression of Stromal Cell-Derived Factor-1 by Mesenchymal Stromal Cells Impacts Neutrophil Function During Sepsis.

Authors:  Min-Young Kwon; Sailaja Ghanta; Julie Ng; Konstantin Tsoyi; James A Lederer; Roderick T Bronson; Souheil El-Chemaly; Su Wol Chung; Xiaoli Liu; Mark A Perrella
Journal:  Crit Care Med       Date:  2020-05       Impact factor: 7.598

Review 2.  Emergency granulopoiesis.

Authors:  Markus G Manz; Steffen Boettcher
Journal:  Nat Rev Immunol       Date:  2014-04-22       Impact factor: 53.106

3.  Utility of immature granulocyte percentage in pediatric appendicitis.

Authors:  Eleanor K Mathews; Russell L Griffin; Vincent Mortellaro; Elizabeth A Beierle; Carroll M Harmon; Mike K Chen; Robert T Russell
Journal:  J Surg Res       Date:  2014-04-12       Impact factor: 2.192

Review 4.  Myelopoiesis in the Context of Innate Immunity.

Authors:  Ioannis Mitroulis; Lydia Kalafati; George Hajishengallis; Triantafyllos Chavakis
Journal:  J Innate Immun       Date:  2018-06-06       Impact factor: 7.349

5.  Myeloid commitment shifts toward monocytopoiesis after thermal injury and sepsis.

Authors:  S Santangelo; R L Gamelli; R Shankar
Journal:  Ann Surg       Date:  2001-01       Impact factor: 12.969

6.  Delta neutrophil index as an early marker of disease severity in critically ill patients with sepsis.

Authors:  Byung Hoon Park; Young Ae Kang; Moo Suk Park; Won Jai Jung; Su Hwan Lee; Sang Kook Lee; Song Yee Kim; Se Kyu Kim; Joon Chang; Ji Ye Jung; Young Sam Kim
Journal:  BMC Infect Dis       Date:  2011-11-01       Impact factor: 3.090

7.  Angptl4 is upregulated under inflammatory conditions in the bone marrow of mice, expands myeloid progenitors, and accelerates reconstitution of platelets after myelosuppressive therapy.

Authors:  Anne Schumacher; Bernd Denecke; Till Braunschweig; Jasmin Stahlschmidt; Susanne Ziegler; Lars-Ove Brandenburg; Matthias B Stope; Antons Martincuks; Michael Vogt; Dieter Görtz; Annalisa Camporeale; Valeria Poli; Gerhard Müller-Newen; Tim H Brümmendorf; Patrick Ziegler
Journal:  J Hematol Oncol       Date:  2015-06-09       Impact factor: 17.388

8.  Delta neutrophil index as an early marker for differential diagnosis of adult-onset Still's disease and sepsis.

Authors:  Hee-Jin Park; You-Jung Ha; Jung-Yoon Pyo; Yong-Beom Park; Soo-Kon Lee; Sang-Won Lee
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

Review 9.  Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy.

Authors:  Patrick Innamarato; Shari Pilon-Thomas
Journal:  Cell Immunol       Date:  2020-12-26       Impact factor: 4.868

10.  Revisiting the white blood cell count: immature granulocytes count as a diagnostic marker to discriminate between SIRS and sepsis--a prospective, observational study.

Authors:  Axel Nierhaus; Stefanie Klatte; Jo Linssen; Nina M Eismann; Dominic Wichmann; Jörg Hedke; Stephan A Braune; Stefan Kluge
Journal:  BMC Immunol       Date:  2013-02-12       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.